Bionical Emas Strengthens Leadership in Early Access Programs and Clinical Trial Supply
Bionical Emas, a global frontrunner in Early Access Programs (EAP) and Clinical Trial Supply (CTS), is set to reinforce its market position by focusing sharply on its core services. This strategic transformation comes with the sale of its Clinical Development division, EMAS Pharma, to Kester Capital and a newly appointed executive team—marking a significant step in Bionical’s growth trajectory.
Strategic Divestment of Clinical Development Division
Following a thorough strategic review earlier this year, Bionical made the decision to divest its Clinical Development arm, EMAS Pharma. Financial details of the transaction have not been disclosed. This move enables Bionical to concentrate resources and investments on enhancing its established businesses: Early Access Programs and Clinical Trial Supply.
The divestiture allows Bionical to streamline operations and expand its global footprint by delivering more tailored and specialized clinical services aligned with the company’s mission—helping patients worldwide gain access to crucial medications.
Focus on Early Access Programs and Real World Data
Early Access Programs are designed to provide patients with serious or life-threatening conditions access to treatments that would otherwise be unavailable to them before regulatory approval. This area forms a critical part of Bionical’s commitment to patient care globally.
Beyond access, Bionical plans substantial investment in Real World Data initiatives and specialized clinical services to complement and enhance its Early Access Programs. This will further differentiate their service offerings and benefit pharmaceutical and biotech clients seeking innovative solutions.
Enhancing Clinical Trial Supply Capabilities
The Clinical Trial Supply division of Bionical Emas ensures global availability of medicines and ancillary products necessary for clinical trials. To propel growth and strengthen strategic capabilities in this sector, Richard Lambie will join the Executive Leadership Team as Executive Vice President of Clinical Trial Supply. Lambie brings over ten years of experience managing high-performing teams within the clinical supply marketplace.
These leadership changes affirm Bionical’s commitment to maintaining its competitive edge and delivering superior service quality to clients.
Continuity in Leadership
Tom Watson remains the Chief Executive Officer of Bionical Emas, with the existing Executive Management team continuing their stewardship of the company. Watson expressed enthusiasm about the strategic move, emphasizing the company’s ambition to become a truly global provider of Early Access Programs and Clinical Trial Supply.
He also highlighted the positive prospects for the newly independent EMAS Pharma, now backed by Kester Capital and an experienced management team recognized for growing Contract Research Organizations (CROs).
Executive Insights from Tom Watson, CEO
“We are excited to accelerate our mission to help patients in urgent need worldwide. This strategic divestment allows us to sharpen our focus and offer unique, tailored solutions that meet our clients’ evolving needs. We are equally pleased with the future platform created for EMAS Pharma under its new leadership and ownership,” Watson said.
He concluded with gratitude toward all parties involved in enabling this transition and optimism about Bionical’s future performance in 2025.
About the Companies
Bionical Emas
Bionical Emas is a global organization specializing in Early Access Programs and Clinical Trial Supply. The company partners with many leading pharmaceutical and biotech enterprises to bring critical medicines to patients around the world through innovative clinical and access services.
EMAS Pharma
EMAS Pharma is a full-service Clinical Research Organization offering customized clinical trial support across multiple therapeutic areas, including oncology, rare diseases, inflammation, immunology, and microbiome therapeutics. The company is now operating independently under new ownership by Kester Capital and a leadership team focused on growth and innovation in the CRO sector.
Kester Capital
Kester Capital is a UK-based private equity firm focusing on lower mid-market investments in life sciences and technology. It aims to provide capital and strategic support to businesses with strong growth potential, helping them unlock new opportunities and scale their operations.
Moving Forward
This strategic reshaping of Bionical Emas marks a new era of focused leadership and global expansion in Early Access Programs and Clinical Trial Supply. With strengthened executive capabilities and increased investment in data and specialized services, the company is well-positioned to deliver life-changing medicines to patients worldwide more efficiently than ever before.